Skip to main content
. 2021 Jun 15;2021:9993229. doi: 10.1155/2021/9993229

Table 2.

Characteristics of included studies.

Study Year Liraglutide intervention LG/CG LVEF (%) e′ (cm/s) E/e Heart rate (bpm)
Kumarathurai et al. [18] 2021 0.6 mg/day, increased every 14 days up to 1.8 mg/day LG 58.9 ± 7.2 5.7 ± 1.6 15.36 ± 6.4 68.6 ± 10.1
CG

Paiman et al. [19] 2020 0.6 mg/day, increased every 7 days up to 1.8 mg/day LG 56 ± 8 5.3 ± 2.1 7.4 ± 3.9 73 ± 13
CG 57 ± 7 5.7 ± 1.9 7.4 ± 3.3 77 ± 11

Wagner et al. [20] 2019 0.6 mg/day, increased every 7 days up to 1.8 mg/day LG 62 ± 7 NR 8.8 ± 2.3 NR
CG 64 ± 5 9.7 ± 2.6

Bizino et al. [21] 2019 0.6 mg/day, increased every 7 days up to 1.8 mg/day LG 55 ± 5.8 6.0 ± 1.6 7.3 ± 2.9 70 ± 9
CG 55 ± 4.5 6.0 ± 1.8 7.9 ± 2.3 70 ± 12

Jorgensen et al. [22] 2017 0.6 mg/day, increased every 7 days up to 1.8 mg/day LG 59.2 ± 6.1 NR 8.1 ± 1.9 80.4 ± 8.5
CG 60.7 ± 6.6 8.2 ± 2.3 81.3 ± 8.3

Zhang et al. [23] 2017 0.6 mg/day for 2 days, 1.2 mg/day for 2 days, 1.8 mg/day for 3 days LG 42.2 ± 7.1 NR NR 67 ± 10
CG 42.1 ± 7.3 67 ± 11

Jorsal et al. [24] 2017 0.6 mg/day, increased every 7 days up to 1.8 mg/day LG 33.7 ± 7.6 6.6 ± 2.1 12.6 ± 6.0 76.3 ± 15.1 75.1 ± 9.6
CG 35.4 ± 9.4 6.9 ± 2.4 11.7 ± 5.5

Chen et al. [25] 2016 0.6 mg/day for 2 days, 1.2 mg/day for 2 days, 1.8 mg/day for 3 days LG 47.2 ± 5.1 NR NR 71.7 ± 12.1
CG 47.7 ± 5.1

Kumarathurai et al. [26] 2016 0.6 mg/day, increased every 14 days up to 1.8 mg/day LG 58.9 ± 7.6 NR NR NR
CG

Chen et al. [27] 2016 1.8 mg before intervention, 0.6 mg/day for 2 days, 1.2 mg/day for 2 days, 1.8 mg/day for 3 days LG 51.3 ± 8.1 NR NR NR
CG 50.7 ± 7.6

LG: liraglutide group; CG: control group; NR: not reported; LVEF: left ventricular ejection fraction; E: the value early diastolic filling velocity; e′: the mitral annular early diastolic velocity.